Stock fact sheet · data as of

Labcorp Holdings Inc. (LH): fair value, margin of safety and Wheel Score

Healthcare · Medical - Diagnostics & Research · United States · Blend

Close325.07
GLS fair value187.719 of 9 models
Margin of safety-73%price above fair value
Wheel Score56Fairout of 100
Health8/9Piotroski F-score
Moat4.6/10GLS 10-year score
Market cap$26.4B542k shares a day
Implied vol.30%near-the-money, 20-60 d
P/E26.5EPS 12.27
Dividend yield0.89%payout 24%
Beta0.85about the market
Next earnings27 Oct 2026in 11 days (before the open)

Is LH undervalued?

LH closed at 325.07 on 16 Oct 2026, more than 30% above the GLS average fair value of 187.71. Only 1 of the 9 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.

The 9 models disagree widely: GLS Growth gives 5.50 while 10 Cap gives 374.56. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.

The nightly engine files LH under Blend.

Nine valuation models for LH

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF309.73-5%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number170.53-48%The most a defensive investor pays for the earnings and book value per share
Graham Growth309.39-5%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch106.07-67%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth5.50-98%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap374.56+15%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time234.90-28%Eight years of compounded free cash flow: the price at which the business pays for itself
DDM42.38-87%Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend
EPV136.31-58%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)-70.72-122%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target346.57+7%Analysts' average 12-month price target. Not in the average

Quality and financial health

On financial health LH scores 8/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is low at 4.6 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are moderate - ROIC 5.5%, ROE 10.2%, ROA 4.8% - with debt at 0.84 times equity and a free-cash-flow yield of 4.4%.

The dividend yield is 0.89% with a payout ratio of 24% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from LabCorp Diagnostics 78%, Biopharma Laboratory Services 22% (quarter Q2 FY2026).

Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 1/10 on the GLS smart-money scales.

Piotroski F-score8 / 9ROIC5.5%
GLS Moat4.6 / 10ROE10.2%
Debt / equity0.84ROA4.8%
Free-cash-flow yield4.4%Payout ratio24%
Institutions10 / 10Insiders · Congress1 · 1 / 10

Wheel Score 56: Fair

LH scores 56 out of 100 on the Wheel Score (Fair band, 50-64): a usable but unremarkable fit for the wheel strategy. The parts: Value 0/25, Health 18/20, Moat 7/15, Premium 15/20, Stability 17/20. Value (0/25) is where the points are missing.

Implied volatility is 30% on the near-the-money contracts 20-60 days out: some premium, but under the 35-60% range the Wheel Score pays full marks for (15 of 20 points). Chain open interest is 4,666 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 542k shares a day on a market cap of $26.4B, with a beta of 0.85; the Stability part of the Wheel Score gives that 17 of 20.

PartPointsFrom
Value0 / 25-73% margin of safety
Health18 / 20Piotroski 8/9
Moat7 / 15moat 4.6/10
Premium15 / 20implied volatility 30%
Stability17 / 20542k shares/day, $26.4B cap, beta 0.85

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

Labcorp Holdings Inc. reports earnings on 27 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Diagnostics & Research

The 12 companies below are the closest to Labcorp Holdings Inc. by market cap within the Medical - Diagnostics & Research industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
DGX
Quest Diagnostics Incorporated
239.01149.02-60%58Fair$26.4B
GH
Guardant Health, Inc.
165.88--45Weak$22.3B
MTD
Mettler-Toledo International Inc.
1,639.04647.54-153%60Fair$32.8B
MEDP
Medpace Holdings, Inc.
628.60504.82-25%65Good$17.5B
ILMN
Illumina, Inc.
267.93113.15-137%58Fair$40.5B
RVTY
Revvity, Inc.
152.1753.29-186%62Fair$17.0B
WAT
Waters Corporation
436.9185.55-411%57Fair$42.9B
IDXX
IDEXX Laboratories, Inc.
547.18377.99-45%70Good$43.1B
IQV
IQVIA Holdings Inc.
271.04193.82-40%65Good$44.6B
CRL
Charles River Laboratories International, Inc.
306.24137.46-123%45Weak$14.8B
A
Agilent Technologies, Inc.
175.5572.05-144%62Fair$49.5B
ICLR
ICON Public Limited Company
175.13140.71-24%61Fair$13.5B

⚖ Compare LH with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about LH

Is LH undervalued right now?

No: at 325.07 the stock trades 73% above the GLS average fair value of 187.71 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of LH and what does it mean?

LH scores 56 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for LH?

187.71 per share as of 16 Oct 2026 - the simple average of the 9 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Labcorp Holdings Inc. report earnings next?

The next earnings report is due on 27 Oct 2026 (before the open), 11 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does LH have listed options, and how liquid are they?

Yes. The nightly snapshot found 440 listed contracts with 4,666 open interest across all expiries and implied volatility of 30% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.